参附注射液为主治疗慢性肺原性心脏病心力衰竭的疗效观察

Observation on Therapeutic Efficacy of Chinese Medicine plus Western Medicine Treating Heart Failure due to Chronic Pulmonary Heart Disease

目的 观察参附注射液、黄芪注射液与川芎嗪注射液配合西医常规疗法治疗慢性肺原性心脏病心力衰竭的临床疗效。方法将60例慢性肺原性心脏病心力衰竭患者随机分为治疗组32例和对照组28例，对照组采用西医常规治疗，治疗组在西医常规治疗的基础上加用参附注射液、黄芪注射液和川芎嗪注射液治疗，比较两组疗效。结果治疗组总有效率93．75％、对照组53．57％，两组疗效有显著性差异（P〈0．01）；病死率治疗组为0、对照组为17．86％，两组比较有显著性差异（P〈0．05）。结论参附注射液、黄芪注射液和川芎嗪注射液治疗慢性肺原性心脏病心力衰竭可降低肺动脉压、改善心功能、降低病死率，疗效显著。

Objective To observe the therapeutic efficacy of combined use of ＂shen fu＂ injection（参附注射液）, astragalus injection and tetramethylpyrazine injection in the treatment of heart failure due to chronic pulmonary heart disease. Methods 60 cases were randomly divided into a control guoup （n=28）, which was treated with routine therapy and a treatment group （n=32）, which was treated with ＂shen fu＂ injection, astragalus injection and tetramethylpyrazine injection on basis of routine therapy. Results The total effective rates were 93.8% and 53.6% in the treatment group and the control group respectively, demonstrating a obvious difference between the 2 groups （P〈0.01）. The mortality is zero in the treatment group comparing with 17.9% in the control group, showing obvious difference between the 2 groups （P〈0.05） .Conclusion Combined use of ＂shen fu＂ injection, astragalus injection and tetramethylpyrazine injection can decrease pulmonary artery pressure, improve cardiac performance and decrease mortality in the treatment of heart failure due to chronic pulmonary heart disease.